Clients

Galectin Therapeutics Inc.

Company Snapshot: Galectin Therapeutics Inc.

GALT
Last Change Volume High Low

Company Overview

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.

Featured Documents

Client News

  1. Jun 27 2018 Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
  2. Jun 22 2018 Company Profile for Galectin Therapeutics Inc.
  3. Jun 12 2018 Galectin Therapeutics Inc. Announces New CEO
  4. Jun 4 2018 Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board